Pulmonary vascular phenotype in adults with COPD.
Official title: Clinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease - a Retrospective Multi-center Data Analysis
Run by Medical University of Graz · NCT07102823 · Data updated 2026-11-12
This registry collects right-heart catheterization and clinical data from adults with COPD to better understand pulmonary hypertension in this group.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Medical University of Graz Academic / other |
| Locations | 3 sites (Graz and 2 other locations) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | December 30, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | January 14, 2026 |
| Trial ID | NCT07102823 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with a clinical diagnosis of COPD who have undergone right-heart catheterization with documented mPAP, PVR, PAWP, and CO are ideal candidates.
✕Probably not a fit
Pediatric patients, people without COPD, or those who have not had right-heart catheterization or lack complete hemodynamic data are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter observational registry enrolling adults with a clinical diagnosis of COPD who have undergone right-heart catheterization. Key hemodynamic measures recorded include mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), pulmonary artery wedge pressure (PAWP), and cardiac output (CO), along with standard clinical data. Sites include the Medical University of Graz, University of Zurich, and University of Sheffield, and the project focuses on detailed phenotyping rather than testing treatments. Patients under 18 or those without RHC data are excluded, and the registry aims to correlate hemodynamics with clinical presentation and outcomes.
Why it matters
Potential benefit: If successful, the registry could help identify COPD subgroups with clinically important pulmonary vascular disease and guide earlier diagnosis and tailored management.
How similar studies have gone: Previous single-center series and registries have described pulmonary hypertension in COPD, but comprehensive multicenter RHC-based phenotyping of this 'pulmonary vascular phenotype' remains relatively limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * clinical diagnosis of COPD * right heart catheterization including mPAP (Mean Pulmonary Artery Pressure), PVR (Pulmonary Vascular Resistance), PAWP (Pulmonary Artery Wedge Pressure), CO (cardiac output) * age \>= 18 years Exclusion Criteria: * pediatric patients * no COPD or no RHC
Where it's running
-
Medical University of Graz
Graz, Austria Recruiting -
University of Zurich
Zurich, Switzerland Recruiting -
University of Sheffield
Sheffield, United Kingdom Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
Levosimendan to see if it helps the heart after PEA in CTEPH
This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.
-
IOS-based platform to screen, diagnose, and manage COPD and asthma
This study tests an Impulse Oscillometry system to screen for and diagnose COPD and asthma and to help predict flare-ups over about a year, involving adults in China.
-
Targeted NMES to improve breathing and leg/extra muscle strength in COPD
This study tests whether targeted neuromuscular electrical stimulation helps people with COPD see improvements in breathing muscle function and overall muscle strength.
-
AERO-007: a inhaled LABA+LAMA combination for COPD through a nebulizer
This study tests whether a nebulized LABA+LAMA combination can improve lung function in adults with COPD.
-
PBMT with a pulmonary rehab program for COPD patients
A small randomized trial tests whether adding photobiomodulation therapy before exercise in a COPD pulmonary rehab program helps improve functional capacity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.